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Abstract
Background: Liver fibrosis represents a significant and severe health care problem and there are
no efficient drugs for therapy so far. Preventing the progression of fibrogenesis and revival
endogenous repair activities is an important strategy for both current and future therapies. Many
studies of liver fibrosis consist of animal testing with various hepatotoxins. Although this method
is often used, the model at which cirrhosis or extensive fibrosis becomes irreversible has not been
well defined and is not representative of early-stage fibrogenesis. We here report the establishment
of a transient and reversible liver fibrosis animal model which may better represent an early and
natural fibrotic event. We used a high-speed intravenous injection of naked plasmid DNA of
transforming growth factor-β1 (TGF-β1) gene which is under the control of a metallothionein-
regulated gene in a pPK9A expression vector into the tail vein (the hydrodynamics-based transfer)
and fed the mouse with zinc sulfate (ZnSO4)-containing water simultaneously.
Results: Using our hydrodynamics-based gene transfer model we found that upon induction by
ZnSO4, the serum TGF-β1 level in Balb/c mice and Sp1 transcription factor binding activity peaked
at 48 h and declined thereafter to a normal level on the 5th day. In addition, mRNA and protein
levels of TGF-β1 in the liver were also upregulated at 48 h. Furthermore, induction of TGF-β1
increased the α-smooth muscle actin (α-SMA), p-Smad2/3, hydroxyproline and collagen 1A2 (Col
1A2) levels in the liver, suggesting a significant liver fibrosis.
Conclusion: Our results show that TGF-β1 in pPK9a-transferred mice liver with ZnSO4 feeding
can achieve a high expression level with significant fibrosis. However, since TGF-β1 induction is
transient in our model, the fibrotic level does not reach a large scale (panlobular fibrosis) as seen
in the CCl4-treated liver. Our model hence represents a dynamic and reversible liver fibrosis and
could be a useful tool for studying early molecular mechanism of fibrogenesis or screening of
antifibrotic drugs for clinical use.
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Background
The development of liver fibrosis, particularly in the cir-
rhosis stage, is associated with high morbidity and mortal-
ity rates [1] and at present the only curative treatment for
end stage liver cirrhosis is organ transplantation. The
point at which cirrhosis or extensive fibrosis becomes irre-
versible has not been well defined [2], however, since liver
fibrosis is a continuous process in both gene expression
and histopathological alterations [3]. Generally accepted
animal testing of liver fibrosis includes treatments with
hepatotoxins such as carbon tetrachloride (CCl4). How-
ever, after the cessation of the long-term treatment of CCl4
for more than 4 weeks, pathological changes in the liver,
such as inflammation, are reversed with the exception of
fibrosis [3]. Many experimental long-term treatment mod-
els of liver fibrosis leading to cirrhosis have been useful
for testing drug effectiveness but further studies are
required to account for effects of disease treatment when
gene expressions, especially TGF-β1 gene, has not yet been
irreversibly altered [4].
TGF-β1, a 25-kD multifunctional cytokine, has been dem-
onstrated in a number of animal models to play a major
role in the pathogenesis and progression of fibrotic dis-
ease [5]. Over expression of TGF-β1 presents not only an
early gene change in liver fibrosis but also a direct connec-
tion between oxidative stress and collagen upregulation in
the fibrosis event [6-8]. Hepatic fibrosis results from a net
increased synthesis and decreased degradation of extracel-
lular matrix (ECM) proteins, whose most prevalent pro-
tein is Type 1 collagen (Col 1A2). TGF-β1 regulates ECM
accumulation in the liver via the generation of reactive
oxygen species (ROS) which stimulates calcium (Ca2+)
influx and induces the activation and contraction of
hepatic stellate cell (HSC) [8]. The activated HSC in turn
secretes TGF-β1, further augmenting the autocrine regulat-
ing cycle.
Another involved pathway is the activation of Smad cas-
cade. The Col 1A2 gene expression is induced via the
phosphorylation of Smad2 and Smad3, a Smad contain-
ing complex is subsequently translocated into cell nucleus
[9]. Studies have shown that synergistic cooperation
between Sp1 and Smad3/Smad4 is required for the TGF-
β1 response to the collagen gene expression and Sp1 is
found to play a critical role in the constitutive expression
of Col 1A2 [10]. Cross-talk perhaps exists between these
two pathways [8].
The goal of our current investigation is to establish a liver
fibrosis model in which the spontaneous reversal of fibro-
sis is made possible at an early phase. We used a metal-
lothionein-regulated TGF-β1 expression vector (pPK9a)
in which the fused TGF-β1 gene is under the control of an
inducible metallothionein promoter [11]. This inducible
system has been reported to achieve a high-level of trans-
gene expression in the liver when the system is accompa-
nied with the concurrent presence of heavy metal [12].
Hydrodynamics-based gene delivery has attracted a lot of
attention in recent years [13]. This procedure involves a
large-volume and high-speed intravenous injection of
naked plasmid DNA into the animal tail vein; the proce-
dure represents an efficient, simple and convenient trans-
fection method for laboratory animals. The method
especially allows the achievement of a high expression
level of exogenous gene in liver [12-15]. Combining a
hydrodynamics-based gene delivery system and the met-
allothionein-regulated pPK9a vector, we have established
a dynamic mouse liver fibrosis model. In this model the
level of TGF-β1 gene can be overexpressed with the pres-
ence of zinc sulfate (ZnSO4) in the drinking water. In
induced state Col 1A2 and α-SMA, the two indicators of
fibrosis and HSC activation, are also upregulated. This
model could be useful for studying the initial stages of
liver fibrosis.
Results and Discussion
Expression of TGF-β1 gene in hydrodynamics-based gene 
transferred mice
The level of TGF-β1 was assessed by using four independ-
ent methods: analysis of TGF-β1 in plasma (Fig. 1A),
mRNA (Fig. 1B) and protein (Fig. 1C) in the liver and
immunohistochemical staining in liver sections (Fig. 1D).
The results indicate that serum levels of TGF-β1 in pPK9a-
transferred mice fed with ZnSO4 peaked at 48 h and were
higher than the four control groups (Fig. 1A). In the
absence of ZnSO4 and pPK9a the serum TGF-β1 level is
much lower than in their presence (Fig. 1A). The serum
TGF-β1 values fell between 600 and 900 pg/ml and were
5 to 15 times higher than the controls (Fig. 1A); the peak
was followed immediately by a decline at the 72nd h even
when ZnSO4 was not withdrawn. The level of TGF-β1
declined to its normal level on the 5th day and was no
longer inducible on the 7th day (Fig 1E). The results are
basically similar to that described by Herweijer et al. who
showed time course of gene expression after plasmid DNA
gene transfer to the liver: expression of the transferred
gene was very high on day1 after portal vein injection of
plasmid but diminished quickly by day 2 and declined to
low level after day 4 [16]. Their induction was apparently
transient as ours. Moreover, Clouthier et al. demonstrated
that upon TGF-β1 gene transfer the mice showed similar
pathological morphology in both liver and kidney [17].
As observed by them we also find high expression of TGF-
β1 in the kidney (data not shown), although in this study
we just report our findings on fibrotic events in the liver.
Measurements of the other three analyses were taken at
the 48th h and similar results were seen in mRNA and pro-
tein expressions in liver tissue (Fig. 1B, C and 1D). Prim-Comparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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ers specific for porcine TGF-β1 in pPK9a were used for
distinguishing transcripts from endogenous mouse TGF-
β1 by RT-PCR assay (Fig. 1B). TGF-β1 mRNA was detected
in mice with pPK9a-transfer (Fig. 1B lane 1 and 2) but not
in those without (Fig. 1B lane 3 and 4). However, in west-
ern blot a very trace amount of protein was detected in
mice without pPK9a-transfer (Fig. 1C, lane 3 and 4). This
could be due to fact that the antibody used in the experi-
ment can recognize TGF-β1 from mice, human and por-
cine. This trace amount of protein was barely detected in
immunohistochemical staining of the liver sections (Fig.
1D II).
The high level of TGF-β1 was accompanied by a strong
activation of HSC, as indicated by high expressions of α-
SMA and p-Smad 2/3 (Fig. 1C, lane 2). Prominent bands
of α-SMA and p-Smad 2/3 were also detected in pPK9a-
transferred mice that ingested water in the absence of
ZnSO4 (Fig. 1A, lane 3; 1B, lane 3; 1C, lane 1; and 1D I).
It was reported that a very low level of cadmium is con-
sumed from the diet and this metal ion can induce endog-
enous metallothionein to express to some extent [18]. We
suspect that the cadmium might cause the endogenous
metallothionein induction as shown in Fig. 1C (lane 1).
However, the effect of ZnSO4 on pPK9a became more
drastic as shown in Fig. 1D where TGF-β1 was barely
detected in D I (without ZnSO4) as compared to the bril-
liant staining in D III (with ZnSO4). The levels of TGF-β1
expression in liver pPK9a-transferred mice treated with
ZnSO4 were upregulated at day 2 and declined at day 3–5
(Fig. 1E). Taken together, the results indicated that TGF-
β1 can be markedly induced in pPK9a-tranferred mice
treated with ZnSO4.
Conditional regulation of TGF-β1 expression in mice Figure 1
Conditional regulation of TGF-β1 expression in mice. (A) Serum TGF-β1 levels in hydrodynamics-based gene trans-
ferred mice. Values are represented as mean ± SD. *, p < 0.01; compared with pPK9a alone (48 h); #, p < 0.05; compared with 
pPK9a + ZnSO4 (24 h); and, p < 0.05; compared with pPK9a + ZnSO4 (48 h); unpaired t-tests. (B) RT-PCR analysis for TGF-β1 
mRNA expression at 48th h in the liver of gene transferred mice after injection with pPK9a. (C) Protein expression of TGF-β1 
and α-SMA at 48th h in gene transferred mice after injection with pPK9a. (D) Photomicrographs of immunohistochemical anal-
ysis (upper panel) and bright field (lower panel) for TGF-β1 expression at 48 h in liver sections: I. Ringer's solution + pPK9a 
and ZnSO4free. II. Ringer's solution only. III. Ringer's solution + pPK9a + ZnSO4. Bar = 0.2 mm. (E) TGF-β1 protein expression 
between 1 to 5 days.Comparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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Histological and immunohistochemical analyses in 
hydrodynamics-based pPK9a transferred mice
Liver sections were sampled from mice with pPK9a trans-
fer at the 24th and 48th h with water containing ZnSO4
(24, 48 h; Fig. 2A and 2B). The liver samples looked paler
and stiffer than that of the control (Fig. 2C and 2D). Using
Masson's trichrome staining, we noticed the liver sections
from mice with pPK9a transfer and ZnSO4 induction
exhibited a marked perisinusoidal deposition of ECM
found mostly in the direct vicinity of large vessels (Fig. 3B,
I) and a distinct activation of HSC was also observed as
shown by α-SMA expression (Fig. 3A, I). The distribution
and intensity of collagen and α-SMA were different from
that of the control livers where the two proteins were
barely detected (Fig. 3). The sinusoids with an enlarged
diameter were observed in Fig. 3B I–III, which was not
seen in the control (Fig. 3B, IV). However, a bright red
patch is noticeable in TGF-β1-overexpressed liver (Fig.
2B), which appears to be hemorrhagic (Fig. 2B). The
"hemorrhage" was observed in most of our livers overex-
pressing TGF-β1 gene. A similar situation of liver hemor-
rhage was observed by Clouthier et al. who reported that
overexpression of TGF-β1 gene in mice caused not only
severe liver fibrosis but also in the extreme case hemor-
rhage and thrombosis [17]. They attributed the extreme
situation to the results of overexpression of TGF-β1 and
Upregulation of α-SMA and ECM by gene transfer and  ZnSO4 treatment in liver Figure 3
Upregulation of α-SMA and ECM by gene transfer 
and ZnSO4 treatment in liver. (A) Detection of α-SMA 
by immunohistochemistry. Forty eight h after hydrodynam-
ics-based injection of pPK9a, the mice were sacrificed and 
the liver sections were subjected to immunostaining. Dark 
brown granules represent α-SMA signals stained by α-SMA-
specific antibody and indicated by arrows. (B) Detection of 
ECM and collagen by Masson's trichrome staining. The cyto-
plasm was stained red and collagen fibers in ECM were blue-
green. The collagen signals were indicated by arrows. Repre-
sentative liver sections of α-SMA and collagen from experi-
mental I-IV groups: (I) Ringer's solution + pPK9a + ZnSO4 48 
h. (II) Ringer's solution + ZnSO4. (III) Ringer's solution + 
pPK9a. (IV) Mice without hydrodynamics-based injection. Bar 
= 0.2 mm.
Observation of the liver Figure 2
Observation of the liver. Livers were obtained from mice 
treated with Ringer's solution + pPK9a + ZnSO4 for 24 h (A), 
Ringer's solution + pPK9a + ZnSO4 for 48 h (B), Ringer's 
solution + pPK9a for 48 h (C), and vehicle (injection free) for 
48 h (D).Comparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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not the triggering cause of TGF-β1 overexpression. We
agree with their proposal because we observed a quick
increased expression of TGF-β1 followed by a quick
decline. Should the TGF-β1 expression was caused by liver
damage, we would not have found a prompt decline of
TGF-β1 (Fig. 1A and 1E). More research is definitely
needed to clarify this controversy.
Serum biochemical analysis
Forty eight hours after a hydrodynamics-based injection
of pPK9a, TGF-β1 was induced by ZnSO4 and triggered a
hepatic injury (Fig. 2 and 3B), resulting in increased
alanine transaminase (ALT) levels in the serum of approx-
imately 6 times higher than that of the control groups
(Fig. 4A).
Collagen expression in hydrodynamics-based fibrosis in 
mice
The degree of fibrosis was assessed by using three inde-
pendent methods: the collagen quantitation by measur-
ing hydroxyproline content (Fig. 4B), Col 1A2 mRNA
level in liver samples (Fig. 4C) and the histopathological
analysis under light microscope (Fig. 3B). The results pro-
vide factual evidence that the pPK9a-transferred mice
upon induction by ZnSO4 could strongly elicit the expres-
sions of hydroxyproline and Col 1A2 over 3 folds and 200
folds, respectively, as compared to the normal control
groups (Fig. 4B, C).
HSC activation plays a key role in liver fibrosis at the early
phase and activated HSC is accompanied with high
expressions of p-Smad2/3 and α-SMA proteins
[9,10,19,20]. Our results mirror this fact as shown in Fig.
1C where both proteins are markedly expressed as com-
pared with the controls. Cirrhosis represents a later stage
of progressive scarring in chronic liver disease; it begins
with subendothelial or pericentral fibrosis (hepatic fibro-
sis) and progresses to panlobular fibrosis with nodule for-
mation (cirrhosis) [2]. Our study demonstrates that liver
TGF-β1 of pPK9a-transferred mice with ZnSO4 feeding
can achieve a substantial increased expression level with
fibrosis. However, since our TGF-β1 expression is tran-
sient, the fibrotic level does not reach a large scale (pan-
lobular fibrosis) as seen in the long term CCl4-treated liver
[Additional file 1]. Although this CCl4-induced cirrhosis
model is commonly used, its effect is systemic and no
attempts are made to clarify the influence of CCl4 toxicity
[3]. In this regard, our model is apparently different from
the CCl4 model with respect to TGF-β1; the life of TGF-β1
is transient, dynamic and overexpressed. We also noticed
that the transient overexpression of TGF-β1 in the liver
leads to an increased deposition of ECM around the ves-
sels as well as along the sinusoids (Fig. 3B). This finding is
consistent with the observation described by Ueberham et
al. on transgenic animal models [21].
Observation of liver fibrosis in transgenic mice Figure 4
Observation of liver fibrosis in transgenic mice. (A) 
Serum ALT levels. (B) Hydroxyproline content in liver. (C) 
Col 1A2 mRNA levels measured by real-time quantitative 
PCR. All samples were collected 48 h after gene transfer and 
induction with ZnSO4. Values are represented as mean ± SD. 
*, p < 0.05; **, p < 0.001; compared with other groups; 
unpaired t-tests.Comparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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Gel electrophoretic mobility shift assays (EMSA) for Sp1 
protein
To probe into the down steam effectors of TGF-β1 we refer
to the EMSA assay to see if Sp1 molecule specifically is
involved in the signaling pathway. TGF-β1 being a strong
activator of ECM accumulation stimulates the Col 1A2
gene expression by inducing the binding of a Sp1- and p-
Smad2/3-Smad4-containing complex to Col 1A2
upstream promoter element (-330 bp to -286 bp and -271
bp to -255 bp; TGF-β1 responsive element; TbRE) which
contains a CAGA box. Since Sp1 is a critical mediator of
Col 1A2 expression, we deem it prudent to examine if Sp1
was induced in pPK9a-transferred mice treated with
ZnSO4 and hence performed the supershift assay to con-
firm the Sp1 and Sp3 binding to TbRE. Fig. 5 shows that
the binding activity of Sp1 in liver increased at day 2 and
decreased at day 3–5. The pattern of Sp1 binding strongly
correlates with the expression levels of TGF-β1 (Fig. 1E).
Since it has been reported that Sp1 is required for the early
response of Col 1A2 to TGF-β1 and maintenance of the
constitutive expression of Col 1A2 [20], our results pro-
vide direct evidence confirming that our pattern of fibrosis
model is early, dynamic and reversible. Moreover, Fig. 3A
and 4C show that temporal activation of TGF-β1 and Sp1
is correlated with α-SMA and Col 1A2 expressions, a find-
ing consistent with previous reports [19,20].
Conclusion
The important role played by TGF-β1 in liver fibrosis has
been well documented [5,7,8] and has been shown in
transgenic mice model using pronuclear injection by
standard technique [21]. What we have shown here is a
rapid fibrosis model with transient and reversible over
expression of TGF-β1 and Sp1 transcription factor. The
expression is hence an early event. We infer that the fibro-
sis might also be transient and reversible. However, the
expression of transferred TGF-β1 appears to be systemic,
not restricted to the liver as has been reported by our
observation and by others. But since hydrodynamic gene
transfer coupled with metallothionein promoter and
ZnSO4 induction has been reported to have higher expres-
sion level of the exogenously delivered gene in the liver
[12-15], our model is more unique to the liver and may
have its usefulness for the clinical study of the prevention
of early stage of liver fibrosis.
Methods
Animals
Mice of Balb/c strain were used. All procedures of animal
handling were approved by the Institutional Animal Care
and Use Committee of National Cheng Kung University.
Eight-week-old mice were used in all experiments and
were divided into five groups (n  = 21), fed ad libitum
Enhancement of Sp1 binding activity by gene transfer accompanying with ZnSO4 treatment Figure 5
Enhancement of Sp1 binding activity by gene transfer accompanying with ZnSO4 treatment. (A) Measurement of 
Sp1 binding activity performed by EMSA. Nuclear proteins were extracted from the livers of pPK9a-transferred mice adminis-
trating ZnSO4-contained water for 1–5 days. Two µg of nuclear extract was subjected to 32P-labelled probe and the Sp1-DNA 
complex was analyzed on a 4% native polyacrylamide gel. (B) Confirmation of Sp1 and Sp3 binding by supershift assay. Sp1 and 
Sp3 antibodies were added to the reaction mixtures for supershift assays. The shifted and supershifted bands were indicated by 
arrows.Comparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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standard laboratory feed and water with or without 25
mM ZnSO4 plus 5% sucrose in the animal facility [22].
cDNA construction
TGF-β1 cDNA was constructed in pPK9a vector and was
under the regulation of metallothionein promoter. Cys223
and Cys225 in the TGF-β1 pro-peptide were also converted
to serine, a mutation that results in dissociation of the
pro-peptide and secretion of bioactive TGF-β1 [11]. It has
been found that this mutation does not alter TGF-β1 pro-
duction but does yield a high proportion of mature 25
kDa dimer which is bioactive without acid activation
[11,22]. pPK9a was a gift from Professor Paturu Kondaiah
of the Indian Institute of Science, India.
Amplification and purification of plasmid DNA
The plasmid used for administration was purified with a
purification kit (Qiagen, Hilden, Germany) according to
the manufacturer's instructions.
Hydrodynamics-based transfection
Ten  µg of plasmid (pPK9a) were dissolved in 3.0 ml
Ringer's solution (NaCl 0.154 M, KCl 5.63 mM, and
CaCl2 2.25 mM) and injected into the mouse tail vein in a
short duration of 5–7 s according to the hydrodynamics-
based transfection protocol as described [14]. ZnSO4 (25
mM) was dissolved in the drinking water to activate the
metallothionein promoter and stimulate TGF-β1 expres-
sion [22,23].
Serum TGF-β1 levels
Blood was gathered by puncturing into retro-orbital veins
with a 27 gauge needle and reserved in a tube for 30 min
at 4°C. Serum was separated by centrifugation at 2,640 g
for 3 min at 4°C. TGF-β1 levels were determined by
enzyme-linked immunosorbent assays (ELISA) method
(DuoSet ELISA, R&D Systems, Minneapolis, MN).
Induction of TGF-β1 expression in liver
RNA was isolated from liver tissue by using Trizol Reagent
(GIBCO Life Technologies, Rockville, MD). TGF-β1
mRNA expression was detected by means of RT-PCR with
specific primers that distinguish porcine TGF-β1 transcript
from that of the mouse endogenous TGF-β1. PCR primers
specific for porcine TGF-β1 were: 5'-GAAAGCGGCAAC-
CAAATC-3' and 5'-TGACATCAAAGGACAGCCAC-3'.
Additional primers used for RT-PCR of glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) gene, were 5'-CCCT-
TCATTGACCTCAACTAC-3' and 5'-CCACCTTCTTGATGT-
CATCAT-3'. All RT-PCR reactions were done for 35 cycles
[24].
Western blot analysis
For studying protein expressions of TGF-β1 and α-SMA,
liver tissue was homogenized in a RIPA buffer (50 mM
Tris-HCl, pH 8; 150 mM NaCl; 1%
Nonidet P-40; 0.1% SDS; 1% Triton X-100 plus protease
inhibitors Sigma, St. Louis MO) and centrifuged as
described [25]; supernatant was taken as a whole-cell
lysate. TGF-β1 and α-SMA were electrophoresed under
non-reducing condition on a 12% SDS-polyacrylamide
gel, transferred by electroblotting to a PVDF membrane,
and visualized by immunostaining. Anti-TGF-β1, anti-
phospho-Smad 2/3 (Ser433/435-phosphorylated Smad2/
3; p-Smad2/3), anti-Smad 2/3, anti-GAPDH and anti-α-
SMA antibody (Santa Cruz Bio-technology, Inc., Santa
Cruz, CA) were used as the primary antibodies. Secondary
antibodies were conjugated with horseradish peroxidase
(Bio-Rad Laboratories). The signals were visualized by an
enhanced chemiluminescence system (ECL, Amersham).
Hepatic hydroxyproline content
Hydroxyproline content was determined as reported with
slight modification [25,26]. Briefly, 100 mg of liver sam-
ple were hydrolyzed in 6 M HCl at 110°C for 24 h. After
centrifugation at 2000 rpm at 48°C for 5 min, 2 ml of
supernatant was mixed with 50 ml of 1% phenol-
phthalein and 8 N KOH to pH7–8. A 5 ml sample was
subjected to a spectrophotometer at 560 nm to determine
the content of hydroxyproline.
Biochemical analysis of plasma
Samples of 1 ml blood were gathered from the retro-
orbital plexus of each mouse and immediately centrifuged
at 1,300 g at 4°C while plasma was kept at -20°C for liver
function tests. ALT levels were measured using a colori-
metric analyzer [27] (Dri-Chem 3000, Fuji Photo Film
Co, Tokyo, Japan).
Histological and immunohistochemical analysis of TGF-β1 
and α-SMA expression
Mouse liver tissues were embedded in an optimal cutting
temperature (OCT) compound (Miles Inc., Elkhart, IN)
and frozen in liquid nitrogen. Five µm-thick cryosections
were made by using cryostats (Leica CM 1800, Nussloch,
Germany). The sections were fixed with cold acetone and
endogenous peroxidase was inhibited by 3% H2O2 in
phosphate buffered saline (PBS). Then the sections were
incubated with 5% blocking serum (normal serum of the
species of the secondary antibody). For modeling the neg-
ative control sections, the primary antibodies were substi-
tuted for the appropriate classes and isotypes of normal
immunoglobulins (Igs). Controls for nonspecific binding
of the secondary antibody were performed by replacing
the solutions of the first step with PBS buffer. TGF-β1 was
revealed by using a rabbit polyclonal antibody (SantaComparative Hepatology 2007, 6:9 http://www.comparative-hepatology.com/content/6/1/9
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Cruz Biotechnology, Inc., Santa Cruz, CA), and an anti-
rabbit IgG conjugated with Alexa Fluor 594 (Molecular
Probes, Eugene, OR). For the detection of α-SMA, a mouse
monoclonal antibody was used. Signals were visualized
by anti-mouse IgG-HRP, horseradish peroxidase labeled
secondary antibody, and 3, 3'-diaminobenzidine sub-
strate (Vector Laboratories, Burlingame, CA). All sections
were viewed under a microscope (Leica Mikrosysteme Ver-
trieb GmbH, Bensheim, Germany) [21,25].
Masson's trichrome staining
Liver specimens were preserved in 4% paraformaldehyde
in phosphate-buffered saline and dehydrated in a graded
alcohol series. Following xylene treatment, the specimens
were embedded in paraffin blocks and cut into 5 µm-thick
sections stained with Masson's trichrome as described
[21,25].
Quantitative real-time reverse transcription-polymerase 
chain reaction (RT-PCR) analysis of collagen expression
Total RNA was isolated from the liver tissue by TRIZOL
reagent (Invitrogen, Carlsbad, CA, USA). RT was per-
formed as described [28]. Quantitative real-time PCR was
performed with ABI Prism 7700 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA). One µg of
cDNA was used in each PCR reaction. The housekeeping
GAPDH was used as a reference gene for normalization,
and H2O was used as a negative control. The primers for
the PCR reactions of Col 1A2 U08020 were: 5'-ACCTGT-
GTGTTCCCTACTCA-3' and 5'-GACTGTTGCCTTCGCCTC
TG-3', the reaction was catalyzed by Taq polymerase (Inv-
itrogen Corp, Carlsbad, CA). SYBR Green I DNA-binding
dye generated the fluorescence signals during each of the
35 cycles, in proportion to the quantities of double-
stranded DNA (denaturation 15 s at 95°C, annealing 15 s
at 56°C and extension 40 s at 72°C). Each sample was
analyzed in triplicate. Detection of the PCR products by
agarose gel electrophoresis confirmed the homogeneity of
the DNA products. Relative quantitation was calculated
using the comparative threshold cycle (CT) method [as
described in the User Bulletin #2, ABI PRISM 7700
Sequence Detection System]. Relative quantification of
the Col 1A2 transcript was compared to that of the
untreated negative control by the following formula:
 and calculated ∆CT Col 1A2 = CT Col 1A2 - CT GAPDH
and ∆(∆CT) = ∆CT Col 1A2 - ∆CT negative control [29].
Preparation of nuclear extracts and EMSA
The preparation of liver nuclear extracts was based on the
method described by Chang and Huang with minor mod-
ifications [30]. Fresh liver tissue of 0.1 g was homogenized
with a Polytron (Kinematica) in 1 ml of buffer A (10 mM
HEPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM
potassium chloride, 0.5 mM phenylmethylsulfonyl fluo-
ride, 0.5 mM dithiothreitol, 2 µg/ml leupeptin, 10 µg/ml
aprotinin, 50 mM sodium fluoride, and 1 mM sodium
orthovanadate), incubated on ice for 10 min and then
gently shaken for 10 s. The pellet of the crude nuclei was
collected by centrifugation at 12,000 g for 10 s, resus-
pended in 300 µl of buffer C (20 mM HEPES (pH 7.9),
25% glycerol, 420 mM sodium chloride, 1.5 mM magne-
sium chloride, 0.2 mM EDTA, 0.5 mM phenylmethylsul-
fonyl fluoride, 0.5 mM dithiothreitol, 2 µg/ml leupeptin,
10 µg/ml aprotinin, 50 mM sodium fluoride, and 1 mM
sodium orthovanadate) by vortex for 15 s, and then incu-
bated on ice for 20 min. After centrifugation at 12,000 g
for 2 min, the supernatant containing the nuclear proteins
was collected, quantified with BCA Protein Assay Reagent
(Pierce), and stored at -70°C in aliquots. For EMSA assay
we used the following oligonucleotides: consensus Sp1 (f)
5'-GTT GCG GGG CGG GGC CGA GTG-3' and consensus
Sp1 (r) 3'-AAC GCC CCG CCC CGG CTC ACG-5' and
labeled the probes with 32P-dCTP by fill-in method [30].
Statistics
Results were displayed by means of mean ± SD. Statistical
analysis was carried out by F-test (for confirming homoge-
neity of variances) and two-tailed Student's t-test (for eval-
uating differences between means). P values lower than
0.05 (*) and 0.01 (**) were considered statistically signif-
icant.
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Additional file 1
Liver sections of CCl4-induced fibrosis. Comparative histology of liver 
from mice treated with carbon tetrachloride (CCl4) and hydrodynam-
ics-based transfer TGF-β gene. Liver sections were stained with Masson's 
trichrome. (A) Mice were injected intraperitoneally with 0.3 ml CCl4 
solution (4% CCl4 in corn oil) twice per week for 8 weeks. (B) Ten µg of 
plasmid (pPK9a) was dissolved in 3.0 ml Ringer's solution and injected 
into the mouse tail vein in a short duration of 5–7 s. The mice were fed 
water containing 25 mM ZnSO4ad libitum. The collagen fibers peaked 
at day 2 indicated by arrows. Bar = 500 µm.
Click here for file
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5926-6-9-S1.tiff]